Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000241

EU PAS number

EUPAS1000000241

Study ID

1000000241

Official title and acronym

Detection of therapeutic cascades associated with gabapentinoids and benzodiazepines in adults over 65 years old in Spain using BIFAP through prescription sequence symmetry analysis (GABALOOP)

DARWIN EU® study

No

Study countries

Spain

Study description

Introduction: Increasing awareness of certain therapeutic cascades among healthcare professionals through evidence derived from research is crucial for their prevention. Benzodiazepines and gabapentinoids may be related to two of these cascades, and their prescription is on the rise.

Objective: The main objective is to estimate the rates of sequential drug prescription combinations in the Spanish population aged over 65 with polypharmacy, compared to the rest of the population. Secondary objectives include studying individual factors associated with these combinations.

Material and Methods: The study design is longitudinal and retrospective, using Symmetrical Sequential Prescription Analysis (SSPA). Data from the BIFAP database, which includes primary care information in Spain, will be utilized.

Variables: Prescription times of the drugs considered exposure and event, as well as clinical and sociodemographic variables related to that prescription, will be collected.

Statistical Analysis: The main characteristics of patients with cascades will be described. Sequence ratios will be calculated to identify asymmetry in prescriptions. A multilevel model will be adjusted to analyze individual factors associated with therapeutic cascades.

Discussion: Trends in prescriptions over time and the variety of indications for the studied drugs may limit some of the results. In summary, the protocol focuses on investigating the prevalence and factors associated with therapeutic cascades and polypharmacy in older adults in Spain, using BIFAP data and a symmetrical sequential prescription analysis approach.

Study status

Planned
Research institution and networks

Institutions

Networks

RICAPP

Contact details

Juan A Lopez-Rodriguez

Primary lead investigator
ORCID number:
0000-0002-4985-2314
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
No external funding
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable